FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Tofacitinib

Drug and asset intelligence for Tofacitinib with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Orient Pharma →

Mechanism of action

JAK Inhibitor

Recent signals(3)

StrategyJune 22, 2026

FDA Approves ANDA for Tofacitinib Citrate by MSN

The FDA has approved the ANDA217299 application for Tofacitinib Citrate submitted by MSN.

StrategyJune 21, 2026

FDA Grants Approval for Tofacitinib Citrate ANDA219830 by Orient Pharma

The FDA has granted approval for the ANDA219830 application for Tofacitinib Citrate submitted by Orient Pharma.

Clinical

June 17, 2026

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

— Tofacitinib

June 22, 2026 · N/A

Topline Data

Orient Pharma — Tofacitinib

June 21, 2026 · N/A

Topline Data

Pfizer — Tofacitinib

June 17, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Gastroenterology →

Gastroenterology · Ulcerative Colitis →

Immunology →

Immunology · JAK Inhibitor →

JAK Inhibitor →

Ulcerative Colitis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.